Overview

Vasomotor Symptoms and Cardiovascular Control

Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to preliminarily determine whether the frequency and/or severity of vasomotor symptoms (VMS) at baseline, and then after symptom reduction with gabapentin, relates to various cardiovascular control measures.
Phase:
N/A
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Brigham and Women's Hospital
Spaulding Rehabilitation Hospital
Treatments:
Gabapentin
gamma-Aminobutyric Acid